(PDF) P1.01-61 Clinical Characterization of ERBB2 Exon 20

P1.01-61 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.617

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

OA07 Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

P3.13-13 Afatinib in Lung Adenocarcinoma Harboring De Novo EGFR Exon 20 Insertions.

Journal of Thoracic Oncology

Respiratory Medicine

English

P020 Characterization of Met Exon 14 Skipping and Association With Clinical Outcomes of Crizotinib in Chinese Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-58 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-96 Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy

Journal of Thoracic Oncology

Respiratory Medicine

English

P071 Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-Small Cell Lung Cancer in Korea

Cancer Research and Treatment

Cancer Research

English

P1.01-110 Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated With Afatinib

Journal of Thoracic Oncology

Respiratory Medicine

English

Clinical Efficacy and Safety of Afatinib in the Treatment of Non-Small-Cell Lung Cancer in Chinese Patients

OncoTargets and Therapy

English